Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$13.77
--
Market closed
$13.77
--
Day’s Range― - ―
52-Week Range$8.70 - $40.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)489.64K
Market Cap
$490.73M
Enterprise Value$1.33B
Total Cash (Recent Filing)$304.73M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,575,718
10 Day Avg. Volume352,899
30 Day Avg. Volume489,637
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap2.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.27K
Enterprise Value/Ebitda-5.70
Forecast
1Y Price Target
$26.00Price Target Upside88.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and substantial equity provide MapLight with financial flexibility to fund clinical development and absorb execution setbacks. This capitalization is a durable advantage for an early-stage biotech, although continued cash burn could reduce that flexibility over time.
Positive Schizophrenia Trial DataPositive Phase 2 efficacy, cognitive benefits, and tolerability support ML-007C-MA as the company’s leading value driver. Advancing toward pivotal development could strengthen the pipeline’s commercial potential and improve MapLight’s strategic position in schizophrenia.
Program Funding VisibilityThe combination of existing liquidity and new institutional financing extends the runway for Phase 3 ZEPHYR-2, the VISTA trial, and corporate needs. That funding visibility supports disciplined execution and reduces the immediate need for additional capital.
Bears Say
Pre-revenue Operating ModelMapLight has no commercial revenue to offset research and development spending, leaving earnings dependent on successful clinical progress and eventual commercialization. Until a product reaches market, the company lacks operating leverage and remains reliant on external funding.
Widening Losses And Rising ExpensesThe widening loss reflects a higher expense base as MapLight advances multiple clinical programs. Sustained cost growth can accelerate depletion of its capital base, increase future financing requirements, and make profitability dependent on successful late-stage development.
Clinical Setback In Autism ProgramFailure on the primary endpoint weakens confidence in ML-004’s development path and may limit its near-term contribution to the pipeline. Although an adolescent irritability subgroup showed benefit, further regulatory discussions or partnerships are required to advance the asset.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $8.70 and its highest was $40.43 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $490.73M.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 55,575,718 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.00 (88.82% Upside)
$26.00 (88.82% Upside)
Blogger Sentiment
Neutral
MPLT Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 248.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $65.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 28.4%
Last 30 Days ▲ 28.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-63.84%
Trailing 12-Months
Asset Growth
337.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$26.00
▲(88.82% Upside)
Technical Analysis
Ownership Overview
58.07% Insiders
5.82% Mutual Funds
0.03% Other Institutional Investors
33.24% Public Companies and
Individual Investors